PHP Code

Using the PHP code extracts allows Academic Staff Profiles to be displayed in a number of different styles including the tabbed format shown below - the data is provided dynamically from the IRIS application, while maintaning the consistent look and feel of your site.

Mr Hashim Ahmed

  • Telephone:

    020 3447 9194

  • Extension:

    09368

  • Fax:

    020 3447 9303

  • Email:

    hashim.ahmed@ucl.ac.uk

  • Webpage:

    http://www.ucl.ac.uk/prostate

  • Address:

    3rd Floor, Charles Bell House 67 Riding House Street,
    London,
    W1P 7NN

  • Appointments:

    Clinician Scientist, Research Department of Urology, Div of Surgery & Interventional Sci

Summary

Hashim had held senior house jobs in surgery on the Royal Free Hospital rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital, University College Hospital and Watford General Hospital. He was a Pelican Cancer Foundation Research Fellow followed by a MRC Clinician Research Training fellowship at University College London at which time a number of imaging and focal therapy trials were started. His research interests are in Health Technology Evaluation including multi-parametric MRI, Histoscanning, Tissue Type Imaging, as well as therapeutic interventions such as high intensity focused ultrasound, irreversible electroporation, and photodynamic therapy. He has completed three phase I/II clinical trials evaluating the role of focal therapy in prostate cancer and is Co-PI in a number of multicentre trials including the UK NIHR-HTA funded study PROMIS study evaluating the role of multi-parametric MRI in men with a raised PSA using Template Prostate Mapping as the reference standard as well as INDEX, a multicentre focal therapy study using HIFU with 3 year follow-up. He currently holds a MRC Clinician Scientist Fellowship for 5 years.

 

He currently holds a number of international and national committee memberships:

1. NCRI Prostate Clinical Studies Group, Member, 2012-2015

2. NCRI Prostate Clinical Studies Group (Diagnostic and Localised Disease Sub-group), Member, 2011-2015

3. NCRI Screening, Prevention and Early Diagnosis (SPED) Group, Member, 2012-2015

4. Cochrane Renal Group, Urology Lead Editor, 2010-current

5. European Urology journal, Editorial Board, Member, 2012-current

6. BJU International journal, Consulting Editor (Imaging), 2012-current

Research Summary

1. Diagnosis and risk stratification of localised prostate cancer

2. Tissue preserving focal therapy in the treatment of localised prostate cancer

3. Tissue preserving focal salvage therapy in the treatment of localised radiorecurrent disease

4. Tissue and Imaging biomarker discovery and validation

5. Multicentre trials and novel trial design

6. Imaging registration for targeted interventions

 

 

Research Activities

  • Clinical trials
  • Imaging Biomarkers
  • Prostate cancer
  • imaging

Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

  1. Ahmed HU (2013) Prostate cancer: Time for active surveillance of intermediate-risk disease? Nat Rev Urol, 10(1), 6 - 8. 10.1038/nrurol.2012.213.
  2. Dickinson L,Ahmed HU,Allen C,Barentsz JO,Carey B,Futterer JJ,Heijmink SW,Hoskin P,Kirkham AP,Padhani AR,Persad R,Puech P,Punwani S,Sohaib A,Tombal B,Villers A,Emberton M (2013) Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging, 37(1), 48 - 58. 10.1002/jmri.23689.
  3. Kasivisvanathan V,Dufour R,Moore CM,Ahmed HU,Abd-Alazeez M,Charman SC,Freeman A,Allen C,Kirkham A,van der Meulen J,Emberton M (2013) Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol, 189(3), 860 - 866. 10.1016/j.juro.2012.10.009.
  4. Ahmed HU,Emberton M (2012) Focal Therapy in Prostate Cancer: Future Directions.
  5. Karavitakis M,Ahmed HU,Abel PD,Hazell S,Winkler MH (2012) Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer. J Endourol, 26(5), 503 - 508. 10.1089/end.2011.0345.
  6. Dickinson L,Ahmed HU,Emberton M (2012) Management of Urological Cancers in Older People.
  7. Dickinson L,Ahmed HU,Emberton M (2012) ABC of Prostate Cancer.
  8. Ahmed HU,Muneer A,Arya M,Horenblas S (2012) Textbook of Penile Cancer.
  9. Ahmed HU,Arya M,Carroll PR,Emberton M (2012) Focal Therapy in Prostate Cancer.
  10. Ahmed HU,Arya M,Freeman A,Emberton M (2012) Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol, 13(11), e509 - e517. 10.1016/S1470-2045(12)70388-1.
  11. Punwani S,Emberton M,Walkden M,Sohaib A,Freeman A,Ahmed H,Allen C,Kirkham A (2012) Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. Br J Radiol, 85(1014), 720 - 728. 10.1259/bjr/61380797.
  12. Simmons L,Kirkham A,Ramachandran N,Moore C,Ahmed H,Emberton M (2012) 'Cognitive' MRI-guided TRUS biopsy targeting - does it require specialist radiological expertise? INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 66, 3 - 3.
  13. Abd Alazeez M,Ahmed H,Moore C,Kirkham A,Freeman A,Emberton M (2012) The Role of mp-MRI in the Detection of Prostate Cancer CLINICAL ONCOLOGY, 24(2), 154 - 154.
  14. Stevens DJ,Moore C,Ahmed H,Allen C,Kirkham A,Van der Meulen J,Emberton M (2012) The natural history of untreated prostate MRI lesions in an active surveillance prostate cancer population-260 patient-years EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E1096 - EU281.
  15. Hotston MR,Ahmed HU,Persad R (2012) General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations BJU International, 110(9).
  16. Ahmed HU (2012) Pro Journal of Urology, 187(3), 792 - 794.
  17. Ahmed HU,Wood D,Griffin D,Banks F (2012) Transvaginal cystectomy for complete bladder prolapse British Journal of Medical and Surgical Urology, 5(5), 251 - 253.
  18. Ahmed HU,Emberton M (2012) Focal HIFU for prostate cancer Reply LANCET ONCOLOGY, 13(7), E284 - E284.
  19. Lecornet E,Ahmed HU,Hu Y,Moore CM,Nevoux P,Barratt D,Hawkes D,Villers A,Emberton M (2012) The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol, 188(3), 974 - 980. 10.1016/j.juro.2012.04.104.
  20. Barzell WE,Melamed MR,Cathcart P,Moore CM,Ahmed HU,Emberton M (2012) Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol, 188(3), 762 - 767. 10.1016/j.juro.2012.04.107.
  21. Ahmed HU,Cathcart P,McCartan N,Kirkham A,Allen C,Freeman A,Emberton M (2012) Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer, 118(17), 4148 - 4155. 10.1002/cncr.27394.
  22. Karavitakis M,Ahmed HU,Abel PD,Hazell S,Winkler MH (2012) Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy. Ther Adv Urol, 4(4), 155 - 160. 10.1177/1756287212447092.
  23. Dickinson L,Hu Y,Carter T,Ahmed HU,Allen C,Kirkham A,Emberton M,Barratt D (2012) MR-directed selective HIFU therapy of prostate cancer using a TRUS guidance platform EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E24 - U338.
  24. Ahmed HU,Gabe R,Kaplan R,Parker C,Emberton M,Grp PROMIS (2012) Multi-parametric magnetic resonance imaging in the diagnosis and characterization of prostate cancer prior to first biopsy in men at risk: The PROMIS study EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E824 - U743.
  25. Ahmed HU,Singh P,Dalton E,Stevens D,Barbouti O,Gurung P,Freeman A,Emberton M (2012) Patterns of prostate cancer on template prostate mapping biopsies in 291 men: Implications for focal therapy EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E22 - U334.
  26. Ahmed HU,Arumainayagam N,Kirkham AP,Allen C,Sohaib SA,Freeman A,Emberton M (2012) What burden of prostate cancer can radiologists rule-out on multi-parametric MRI? An analysis based on template prostate mapping biopsies as the reference standard EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E795 - U685.
  27. Ahmed HU,Hindley RG,Dickinson L,Freeman A,Kirkham AP,Sahu M,Scott R,Allen C,Van der Meulen J,Emberton M (2012) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol, 13(6), 622 - 632. 10.1016/S1470-2045(12)70121-3.
  28. Ahmed HU,Emberton M (2012) URINARY INCONTINENCE AFTER PROSTATE CANCER Image guided diagnosis and treatment to prevent incontinence after radical prostatectomy BRITISH MEDICAL JOURNAL, 344. 10.1136/bmj.e1438.
  29. Ahmed HU (2012) Focal Therapy Will Become Standard Treatment for Localized Prostate Cancer JOURNAL OF UROLOGY, 187(3), 792 - 794.
  30. Hu Y,Ahmed HU,Carter T,Arumainayagam N,Lecornet E,Barzell W,Freeman A,Nevoux P,Hawkes DJ,Villers A,Emberton M,Barratt DC (2012) A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int, 110(6), 812 - 820. 10.1111/j.1464-410X.2012.10933.x.
  31. Ahmed HU,Emberton M (2012) Image guided diagnosis and treatment to prevent incontinence after radical prostatectomy. BMJ, 344, e1438.
  32. Langley S,Ahmed HU,Al-Qaisieh B,Bostwick D,Dickinson L,Gomez Veiga F,Grimm P,Machtens S,Guedea F,Emberton M (2012) Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer BJU INTERNATIONAL, 109, 7 - 16. 10.1111/j.1464-410X.2011.10825.x.
  33. Ahmed HU,Emberton M,Kepner G,Kepner J (2012) A biomedical engineering approach to mitigate the errors of prostate biopsy. Nat Rev Urol, 9(4), 227 - 231. 10.1038/nrurol.2012.3.
  34. Nevoux P,Ouzzane A,Ahmed HU,Emberton M,Montironi R,Presti JC,Villers A (2012) Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU Int, 110(4), 517 - 523. 10.1111/j.1464-410X.2011.10776.x.
  35. Ahmed HU,Akin O,Coleman JA,Crane S,Emberton M,Goldenberg L,Hricak H,Kattan MW,Kurhanewicz J,Moore CM,Parker C,Polascik TJ,Scardino P,van As N,Villers A,Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer (appendix) (2012) Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int, 109(11), 1636 - 1647. 10.1111/j.1464-410X.2011.10633.x.
  36. Uddin Ahmed H,Cathcart P,Chalasani V,Williams A,McCartan N,Freeman A,Kirkham A,Allen C,Chin J,Emberton M (2012) Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer, 118(12), 3071 - 3078. 10.1002/cncr.26631.
  37. Hu Y,Ahmed HU,Taylor Z,Allen C,Emberton M,Hawkes D,Barratt D (2012) MR to ultrasound registration for image-guided prostate interventions. Med Image Anal, 16(3), 687 - 703. 10.1016/j.media.2010.11.003.
  38. Karavitakis M,Ahmed HU,Abel PD,Livni N,Hazell S,Winkler MH (2012) Trends in pathologic outcomes after introduction of active surveillance in the UK: implication for focal therapy. Prostate, 72(13), 1464 - 1468. 10.1002/pros.22498.
  39. Ahmed HU (2012) Focal therapy will become standard treatment for localized prostate cancer: pro. J Urol, 187(3), 792 - 794. 10.1016/j.juro.2011.12.023.
  40. Ahmed HU,Emberton M (2012) Focal Therapy in Prostate Cancer: HIFU.
  41. Arya M,Ahmed HU,Scardino P,Emberton M (2011) Interventional Techniques in Uro-oncology.
  42. Karavitakis M,Winkler M,Abel P,Livni N,Beckley I,Ahmed HU (2011) Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis, 14(1), 46 - 52. 10.1038/pcan.2010.16.
  43. Barzell W,Cathcart P,Moore C,Melamed M,Ahmed H,Emberton M (2011) RE-CLASSIFICATION STRATEGIES IN MEN WITH LOW RISK PROSTATE CANCER: TRUS GUIDED BIOPSY VERSUS TEMPLATE PROSTATE MAPPING EUR UROL SUPPL, 10(2), 176 - 176.
  44. Ahmed H,Emberton M,Cathcart P,McCartan N (2011) Determinants of failure in men undergoing salvage high intensity focused ultrasound (sonoblate 500TM) following failed external beam radiotherapy for primary prostate cancer BRITISH JOURNAL OF SURGERY, 98(6), E9 - E9.
  45. Ahmed H,Emberton M,Cathcart P,McCartan N (2011) Focal salvage high-intensity focused ultrasound ablation therapy (Sonoblate 500TM) following failed external beam radiation therapy to the prostate BRITISH JOURNAL OF SURGERY, 98(6), E5 - E5.
  46. Ahmed H,Emberton M,Cathcart P,McCartan N (2011) Whole-gland salvage therapy using high-intensity focused ultrasound (sonoblate 500tm) for presumed local recurrence following external beam radiation therapy to the prostate BRITISH JOURNAL OF SURGERY, 98(6), E4 - E4.
  47. Hu Y,Carter TJ,Ahmed HU,Emberton M,Allen C,Hawkes DJ,Barratt DC (2011) Modelling prostate motion for data fusion during image-guided interventions. IEEE Trans Med Imaging, 30(11), 1887 - 1900. 10.1109/TMI.2011.2158235.
  48. Karavitakis M,Winkler MH,Abel PD,Hazell S,Ahmed HU (2011) Focal therapy for prostate cancer: opportunities and uncertainties. Discov Med, 12(64), 245 - 255.
  49. Dickinson L,Ahmed HU,Emberton M (2011) Re: Salvage Radical Prostatectomy Following Primary High Intensity Focused Ultrasound for Treatment of Prostate Cancer J UROLOGY, 186(3), 1159 - 1160.
  50. Dickinson L,Ahmed HU,Emberton M (2011) Re: Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. N. Lawrentschuk, A. Finelli, T. H. Van der Kwast, P. Ryan, D. M. Bolton, N. E. Fleshner, J. Trachtenberg, L. Klotz, M. Robinette and H. Woo. J Urol 2011;185: 862-868. J Urol, 186(3), 1159 - 1160. 10.1016/j.juro.2011.04.096.

Biography

Hashim had held senior house jobs in surgery on the Royal Free Hospital rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital, University College Hospital and Watford General Hospital. He was a Pelican Cancer Foundation Research Fellow followed by a MRC Clinician Research Training fellowship at University College London at which time a number of imaging and focal therapy trials were started. His research interests are in Health Technology Evaluation including multi-parametric MRI, Histoscanning, Tissue Type Imaging, as well as therapeutic interventions such as high intensity focused ultrasound, irreversible electroporation, and photodynamic therapy. He has completed three phase I/II clinical trials evaluating the role of focal therapy in prostate cancer and is Co-PI in a number of multicentre trials including the UK NIHR-HTA funded study PROMIS study evaluating the role of multi-parametric MRI in men with a raised PSA using Template Prostate Mapping as the reference standard as well as INDEX, a multicentre focal therapy study using HIFU with 3 year follow-up. He currently holds a MRC Clinician Scientist Fellowship for 5 years.

 

He currently holds a number of international and national committee memberships:

1. NCRI Prostate Clinical Studies Group, Member, 2012-2015

2. NCRI Prostate Clinical Studies Group (Diagnostic and Localised Disease Sub-group), Member, 2011-2015

3. NCRI Screening, Prevention and Early Diagnosis (SPED) Group, Member, 2012-2015

4. Cochrane Renal Group, Urology Lead Editor, 2010-current

5. European Urology journal, Editorial Board, Member, 2012-current

6. BJU International journal, Consulting Editor (Imaging), 2012-current

Qualifications

  • 2005: Member of the Royal College of Surgeons, Royal College of Surgeons of Edinburgh
  • 2000: Bachelor of Medicine, Bachelor of Surgery, University of Oxford
  • 1997: Bachelor of Arts (Honours), University of Oxford